A proposal to build a biotechnology research and development facility in Windsor has been temporarily delayed pending regulatory approvals for the parent company’s therapeutic processes, according to town officials.
James Burke, who serves as Windsor’s economic development director, said a consultant for New England Cell Therapeutics told him that the site and incentives portion of the project is on hold as the firm awaits the next steps in the regulatory process. The town expects this may take another six months or so, Burke said.
Officials with New England Cell Therapeutics did not reply to a request for comment.
The biotech firm, which is owned by Japan-based Nipro Group, is considering constructing a 50,000-square-foot facility at 2195 Day Hill Road, which is currently farmland.
Nipro Groups makes medical equipment and test- and diagnosis-related products.
New England Cell Therapeutics had proposed a tax abatement deal for the project. At the time, the company said it would hire 45 full-time employees at the site by 2025.
